Diabeton - hypoglycemic drug that stimulates insulin secretion in the treatment of type 2 diabetes.
The active ingredient - Gliclazide. As the second generation sulfonylureas, Diabeton stimulates insulin release, especially in patients with preserved function of b-cells and increases the second phase insulin. Also, the drug prevents blood clots, a positive effect on blood circulation. It has antiatherosclerotic and antioxidant effect and completely absorbed from the digestive tract.
Prolonged use does not alter renal function and, in a diet promotes reduction of overweight.
The drug is released in the form of several types of white tablets containing different amounts of the active ingredient.
Diabeton. Each tablet contains 80 mg of gliclazide. 30 pieces in blister, 1 or 2 blisters in carton.
Diabeton mV. The modified-release tablet of elongated shape and engraved on one side - the company logo on the other - "DIA30". Each tablet contains 30 mg of gliclazide. 30 pieces in blister, 1 or 2 blisters in carton.
Diabeton 60. The modified-release tablets are oval shaped and engraved with "DIA" "60" on both sides. Each tablet contains 60 mg of gliclazide. 15 pieces in blister, 2 or 4 blisters in a cardboard box and 30 pieces in blister, 1 or 2 blisters in carton.
According to the instructions Diabeton used in non-insulin dependent diabetes mellitus type 2.
The drug is contraindicated in:
- Insulin-dependent diabetes mellitus type 1;
- Diabetic ketoacidosis;
- Severe renal insufficiency, and liver;
- Pregnancy and lactation;
- Severe infections and burns;
- Hypersensitivity to gliclazide or other derivatives of sulfonylurea;
- Miconazole therapy.
Do not prescribe in childhood due to a lack of clinical trials.
Instructions for use Diabeton
Diabeton of instruction is assigned only to adults.
The daily dose may vary from 30 mg to 120 mg depending on the severity of diabetes and glucose. The average daily dose is 60 mg Diabeton, the maximum - 120 mg. Accepted lump sum for breakfast. Crush and chew the tablet can not. You also can not pass when taking the pill to increase the daily dose.
If necessary, increase the dose recommended gradually, but no sooner than a month from the beginning of the reception.
According to responses to Diabeton generally decrease in blood glucose levels observed during the first two weeks of treatment. If it did not, the dosage can be revised before.
The drug can be administered for the combination therapy with biguanide, insulin and a-glucosidase inhibitors.
When switching from Diabeton 80 mg or 60 mg Diabeton Diabeton mV (30 mg), and the transition from treatment saharoponizhayuschimi other oral medications dosage should be adjusted to the attending physician.
According to the instructions Diabeton can cause:
- Various disorders of the gastrointestinal tract: vomiting, diarrhea, nausea, abdominal pain, constipation, in rare cases - cholestatic jaundice;
- Disorders of the cardiovascular system: thrombocytopenia, anemia, leukopenia, or agranulocytosis;
- Various allergic reactions (for reviews of Diabeton - quite rare);
- Temporary visual disturbances associated with changes in blood glucose levels;
The risk of hypoglycemia increases when:
- Irregular or insufficient nutrition, diet changes;
- Renal insufficiency or severe hepatic insufficiency;
- Drug overdose;
- Failure to comply with the doctor's recommendations (especially the elderly);
- Thyroid disease;
- Simultaneous with the appointment of caffeine and some medications (fluconazole, teoffilinom, APF inhibitors and MAO).
To reduce the hypoglycemic effect can Diabeton barbiturates, various diuretic (thiazide, ethacrynic acid, furosemide), progestogens, phenytoin, estrogen, rifampicin, corticosteroids.
Diabeton contraindicated in pregnancy and lactation.
Diabeton assigned to group B, and available on medical prescription. Shelf life - 3 years.